Recent Updates
Recently added Catalysts
IDYA

IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma

Key Takeaway: IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma

Full Press Release Details

IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1 2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma.
Last updated: Nov 29, 2021